Ralph Martini's questions to Can-Fite BioPharma (CANF) leadership • Q3 2020
Question
Ralph Martini, a private investor, asked about the total cost of the terminated Rheumatoid Arthritis study, U.S. patent plans for Namodenoson, the 'fee for service' model for the cannabis assay, and the status of partnership discussions.
Answer
CFO Motti Farbstein reported the RA study cost was between $5 million and $6 million. CEO Pnina Fishman confirmed plans to pursue a U.S. patent for Namodenoson, explained the cannabis assay service identifies clinically active compounds via the A3AR target, and indicated that positive news on partnerships would be forthcoming in a future press release.